Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Short term Debt (2016 - 2024)

Oramed Pharmaceuticals filings provide 11 years of Short term Debt readings, the most recent being $32.0 million for Q1 2024.

  • Quarterly Short term Debt changed N/A to $32.0 million in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $32.0 million through Mar 2024, changed N/A year-over-year, with the annual reading at $51.0 million for FY2023, N/A changed from the prior year.
  • Short term Debt hit $32.0 million in Q1 2024 for Oramed Pharmaceuticals, down from $51.0 million in the prior quarter.
  • Across five years, Short term Debt topped out at $75.4 million in Q3 2023 and bottomed at $43000.0 in Q1 2020.
  • Average Short term Debt over 4 years is $17.6 million, with a median of $90000.0 recorded in 2020.
  • The largest annual shift saw Short term Debt fell 21.82% in 2020 before it soared 102.33% in 2021.
  • Oramed Pharmaceuticals' Short term Debt stood at $93000.0 in 2020, then plummeted by 37.63% to $58000.0 in 2021, then soared by 87853.45% to $51.0 million in 2023, then crashed by 37.2% to $32.0 million in 2024.
  • Per Business Quant, the three most recent readings for ORMP's Short term Debt are $32.0 million (Q1 2024), $51.0 million (Q4 2023), and $75.4 million (Q3 2023).